The Diagnostic Values of Pretreatment Serum Inflammation Markers and Lipoprotein in Men With Total Prostate-Specific Antigen Between 4 and 10 ng/ml

The Diagnostic Values of Pretreatment Serum Inflammation Markers and Lipoprotein in Men With Total Prostate-Specific Antigen Between 4 and 10 ng/ml

Background: The purpose of this study was to analyze the values of pretreatment serum inflammation markers, lipid, and lipoprotein for predicting the pathological results in men with total prostate-specific antigen between 4 and 10 ng/ml.Materials and method: A total of 611 eligible patients diagnos...

Full description

Bibliographic Details
Main Authors:	Guangping Li, Zhenhua Shang, Yihao Liu, Hao Yan, Tongwen Ou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Medicine
Subjects:	prostate cancer inflammation markers lipoprotein lipid prostate biopsy
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2020.576812/full

Similar Items

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
by: Gokhan Koc, MD, et al.
Published: (2017-01-01)

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination
by: Peter Ka-Fung Chiu, et al.
Published: (2016-09-01)

Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice
by: Kyung Tak Oh, et al.
Published: (2020-01-01)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
by: Alexandros Fiamegos, et al.

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
by: W. F. S. Busato, et al.
Published: (2015-04-01)

The sufficiency of 6 core sextant prostate biopsy in patients with prostate specific antigen (PSA) values over 20 ng/mL
by: Cem Yücel, et al.
Published: (2018-06-01)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml-1
by: Cheng Wang, et al.
Published: (2021-01-01)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml−1)
by: Jun Liu, et al.
Published: (2020-01-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
by: Emerson P. Gregorio, et al.
Published: (2007-04-01)

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1
by: Rui Chen, et al.
Published: (2015-01-01)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
by: Hugo A. Socrates Castro, et al.

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
by: Jeremy YC Teoh, et al.
Published: (2017-01-01)

Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL
by: Katia R. Leite, et al.
Published: (2008-06-01)

Prostatic Inflammation in Prostate Cancer: Protective Effect or Risk Factor?
by: Alessandro Tafuri, et al.
Published: (2021-06-01)

Nonspecific Presentation of a Multiloculated Prostatic Abscess After Transurethral Prostatic Biopsy for Elevated Prostate-specific Antigen Level
by: Nilay M. Gandhi, et al.
Published: (2014-11-01)

Chronic inflammation of the prostate type IV with respect to risk of prostate cancer
by: Antonio B. Porcaro, et al.
Published: (2014-09-01)

The results of transrectal prostate biopsy in patients with low levels of prostate specific antigen
by: Ahmet Ali Sancaktutar, et al.
Published: (2012-06-01)

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?
by: Hasan Deliktaş, et al.
Published: (2017-06-01)

Prostatic specific antigen for prostate cancer detection
by: Lucas Nogueira, et al.
Published: (2009-10-01)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
by: Hiroaki Iwamoto, et al.

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
by: Joongwon Choi, et al.
Published: (2020-11-01)

Is It Effective to Perform Two More Prostate Biopsies According to Prostate-Specific Antigen Level and Prostate Volume in Detecting Prostate Cancer? Prospective Study of 10-Core and 12-Core Prostate Biopsy
by: Byung Il Yoon, et al.
Published: (2012-05-01)

Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis
by: Kan HC, et al.
Published: (2017-06-01)

The presence of chronic inflammation in positive prostate biopsy is associated with upgrading in radical prostatectomy
by: Ekrem Guner, et al.
Published: (2021-09-01)

Frequency of Adenocarcinoma in Transrectal Ultrasound-guided Prostate Needle Biopsies in Men with Clinical Suspicion of Prostate Cancer and Raised Serum Prostate Specific Antigen
by: Rahma Rashid, et al.
Published: (2013-04-01)

Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study
by: Antonio Benito Porcaro, et al.
Published: (2015-10-01)

Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml
by: Xuan Wang, et al.
Published: (2016-01-01)

Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy
by: Yong Hyun Park, et al.
Published: (2014-03-01)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml -1 and 10.1-20.0 ng ml -1 : a multicenter study
by: Yu-Rong Lin, et al.
Published: (2015-06-01)

Histopathology, pharmacotherapy, and predictors of prostatic malignancy in elderly male patients with raised prostate-specific antigen levels – A prospective study
by: Dhinesh Kumar Mathaiyan, et al.
Published: (2020-01-01)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1
by: Lincoln GL Tan, et al.
Published: (2017-01-01)

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

Evaluation of the role of digital rectal examination and prostate specific antigen in diagnosis of prostate cancer
by: Harun Çıralık, et al.
Published: (2012-03-01)

Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience
by: Safana S. Al Saidi, et al.
Published: (2017-07-01)

Comparison among different precursor prostatespecific antigen isoform derivatives on prostate cancer prediction in patients with serum prostatespecific antigen bellow 10 ng/ml
by: Stojadinović Milorad M., et al.
Published: (2020-01-01)

Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
by: Kerri Beckmann, et al.
Published: (2019-08-01)

Prostate-specific antigen 10–20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy Gleason score 6
by: Glen Denmer R. Santok, et al.
Published: (2017-03-01)

Decision Tree Analysis for Prostate Cancer Prediction in Patients with Serum PSA 10 ng/ml or Less
by: Pantic Damjan N, et al.
Published: (2020-03-01)

Antibiotics for elevated prostate specific antigen: Where do we stand?
by: Khalid Al Jalham, et al.
Published: (2016-09-01)

Cannot write session to /tmp/vufind_sessions/sess_ahpa9ptvjm7p1sqchld3n6v45e